Articles Raising the bar: can Gilead’s next challenge be even bigger ... How do you follow a genuine drug breakthrough, a cure for hepatitis C?
Articles NICE calls the shots on Harvoni – but NHS England eyeing pri... Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.
News Click claims FDA okay for first-in-class schizophrenia DTx Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
